HKSTP Teams Up with HKU and CUHK Medical Schools to Showcase Hong Kong's Life & Health Innovations at BIO International Convention
Seizing Global Business and Investment Opportunities for Sustainable Growth
HONG KONG SAR – Media OutReach Newswire – 17 June 2025 – Hong Kong Science and Technology Parks Corporation (HKSTP), in collaboration with InvestHK, led 16 prominent life and health technology companies to BIO 2025, the world's largest biotechnology event, held in Boston, USA, from June 16 to 19. This year marks the first time HKSTP joined forces with Hong Kong's two leading medical faculties—the LKS Faculty of Medicine at The University of Hong Kong (HKU) and the Faculty of Medicine at The Chinese University of Hong Kong (CUHK) – to form a delegation, showcasing Hong Kong's cutting-edge research capabilities and innovation potential in life sciences and health technologies. The initiative further strengthens Hong Kong's position as a world-class biotech innovation hub.
In collaboration with InvestHK, HKSTP joined forces with the LKS Faculty of Medicine at The University of Hong Kong (HKU) and the Faculty of Medicine at The Chinese University of Hong Kong (CUHK) for the first time to form a delegation and led 16 prominent life and health technology companies to showcase at BIO 2025 held in Boston, USA.
The HKSTP Pavilion highlighted the groundbreaking technologies and products of its park companies, featuring innovative solutions across diverse fields such as novel drug development, diagnostic technologies, and medical innovation. Among the 16 participating companies, they were the members of HKSTP's incubation programmes including Incu-Bio and ELITE Programme, cutting-edge work from the InnoHK research centers, and other outstanding biotech companies. On the first day of the exhibition, the delegation successfully attracted attention from global industry leaders, corporate partners, and venture capital firms.
ADVERTISEMENT
During BIO 2025, HKSTP and its park companies made significant strides in fostering cross-border innovation ecosystems and exploring new market opportunities:
Immuno Cure , partnering with HKUMed, the developer of the first-in-human novel therapeutic HIV vaccine ICVAX, announced its collaboration with PharmaJet to explore the application of a needle-free vaccination solution, accelerating the global commercialization pathway for ICVAX.
, partnering with HKUMed, the developer of the first-in-human novel therapeutic HIV vaccine ICVAX, announced its collaboration with PharmaJet to explore the application of a needle-free vaccination solution, accelerating the global commercialization pathway for ICVAX. HKSTP signed a partnership agreement with DLRC to provide legal advisory services in clinical trials and certification, promoting global ecosystem collaboration and growth.
Mr. Albert Wong, CEO of HKSTP, said: 'We are thrilled to partner with two leading medical schools for the first time at BIO 2025, demonstrating Hong Kong's breakthroughs and innovation in life and health technology. This delegation not only deepens collaboration between Hong Kong and top global research institutions but also highlights our unique advantages as a core I&T hub in the Greater Bay Area. With strong policy and funding support from the HKSAR government, Hong Kong will further serve as a bridge connecting Mainland China and global tech partnerships, solidifying its leadership in life sciences innovation.'
Ahead of BIO 2025, the delegation participated in the '2025 Biomedical Pitch Competition', co-organized by the Boston Capital Investment Club (BCIC) and HKSTP. The event connects global life and health innovators with investors and business partners. Three HKSTP companies—ARBELE, GenEditBio, and Cogsmart—excelled in the preliminary rounds, competing against over 100 global life sciences firms, with ARBELE, HKUMed's affiliated spin-off company, winning the championship, underscoring Hong Kong's research excellence. Over the past three years, this platform has helped startups secure over USD 100 million in funding and connect with hundreds of international investors and partners, driving further business growth.
HKSTP is committed to propelling Hong Kong's life sciences sector onto the global stage, showcasing the city's unique strengths to attract international enterprises and talent. The delegation also organized networking events and visits, enabling Hong Kong companies to engage with overseas investors, leading corporations, and renowned academic institutions, including visits to MIT Professor Robert Langer (Described as 'Edison of Medicine'), Harvard Innovation Labs, Cambridge Innovation Center, and more. This initiative reinforces Hong Kong's sustainable development in life sciences and its role as a global innovation leader.
Appendix: List of Park Companies Participating in BIO 2025:
ADVERTISEMENT
Allegrow Biotech Limited ARBELE Limited Beth Bioinformatics Co., Limited Centre for Translational Stem Cell Biology The Centre for Virology, Vaccinology, and Therapeutics DECODE CURE Limited GenEditBio Limited Great Bay Bio Hong Kong Universal Biologicals Company Limited Immuno Cure Holding (HK) Limited The Institute for Innovation, Translation and Policy Research (ITPR) LEE'S PHARMACEUTICAL (HK) LIMITED Serilink Biotechnology Company Limited Xiaomo Biotech Limited XUXIN (HongKong) Biotechnology Co., Limited Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited
Hashtag: #HKSTP
The issuer is solely responsible for the content of this announcement.
About Hong Kong Science and Technology Parks Corporation
Hong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 13 unicorns, more than 15,000 research professionals and over 2,300 technology companies from 25 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc.
Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined.
Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more.
Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues to contribute in stablishing I&T as a pillar of growth for Hong Kong. More information about HKSTP is available at www.hkstp.org.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fintech News ME
a day ago
- Fintech News ME
InvestHK's Gulf Cooperation Council Fintech Visit Spurs Strategic Partnerships
Invest Hong Kong (InvestHK) reinforced its role as a global business hub through a strategic visit to the Gulf Cooperation Council (GCC) region, forging strong partnerships. The InvestHK GCC fintech delegation built on the momentum from the Chief Executive's earlier visit to the Middle East in May, which saw three Memoranda of Understanding (MOUs) signed by InvestHK. The InvestHK GCC fintech delegation, made up of leaders from top financial and fintech firms founded locally, in Mainland China or overseas with operations in Hong Kong, engaged in high-level meetings. This included meetings with local government organisations, private equity partners and tech incubators across the GCC, facilitated by InvestHK. The Director-General of Investment Promotion at InvestHK, Alpha Lau, said, 'In today's evolving global economy, Hong Kong has showcased its irreplaceable strategic value as a 'super connector'. We recognise opportunities in high-potential markets, such as the GCC region, which are actively diversifying their economies through innovations. By partnering with InvestHK, companies can effectively access these competitive markets with the government's support.' The Global Head of Financial Services, FinTech & Sustainability at InvestHK, King Leung, added, 'Leveraging our in-depth understanding of each participating company, we successfully showcased Hong Kong as an efficient platform for connecting high-quality enterprises, earning broad recognition from local governments, businesses, and investors across the GCC region.' Over the past two years, firms like Evident Group, LianLian Global, OneDegree, and others have joined the delegations, with delegates crediting the HKSAR Government for enabling meaningful results through its support and connections. Evident Group's delegation participation led to a milestone MOU with Zand Bank, the UAE's AI-powered bank. This marked the start of a strategic collaboration, focused on delivering innovative alternative investment solutions for the latter's private wealth clients. By leveraging Evident Group's secure digital market infrastructure, the partnership aims to broaden access to private equity secondaries, private credit, and tokenised infrastructure, highlighting how digitalisation of private markets can strengthen Hong Kong's role as a bridge for global private wealth. Next, LianLian Global sees Hong Kong as a vital hub for expanding its presence in the GCC. Using InvestHK delegations to build key government-to-government relationships, most notably with the Central Bank of the UAE, opened new strategic pathways. Also, at the Dubai FinTech Summit, LianLian Global secured a cooperation agreement with Lulu Money to extend payment services into Mainland China. Thirdly, Lingfeng Capital secured its approved-in-principle from the UAE's Financial Services Regulatory Authority as a licensed fund manager in the UAE. Lingfeng Capital has set up its regional headquarters in Abu Dhabi after identifying growth opportunities during the first delegation visit last year. Building on this momentum, Lingfeng Capital is now establishing a fund in Abu Dhabi to support portfolio companies from Hong Kong, Mainland China, and beyond as they expand into the GCC region. Finally, OneDegree has earned recognition from GCC government officials for its digital asset insurance solutions. Backed by investment from Dubai Insurance and approved by the Central Bank of the UAE through its partnership with Dubai Insurance Co., OneDegree is set to provide digital asset insurance in the UAE. Walaa will be providing reinsurance capital for OneDegree's global digital asset playbook. A key milestone for OneDegree was a private meeting with senior leadership of the Kingdom of Saudi Arabia's Insurance Authority during last year's delegation visit. The 2025 InvestHK GCC fintech delegation was built on groundwork laid by HKSAR officials to deliver concrete business outcomes, reinforcing Hong Kong's role as a globally connected, outward-facing economy. As a 'super connector' and 'super value-adder,' Hong Kong continues to drive two-way economic growth through innovation and strategic partnerships.
Arabian Post
2 days ago
- Arabian Post
HKSTP Teams Up with HKU and CUHK Medical Schools to Showcase Hong Kong's Life & Health Innovations at BIO International Convention
Seizing Global Business and Investment Opportunities for Sustainable Growth HONG KONG SAR – Media OutReach Newswire – 17 June 2025 – Hong Kong Science and Technology Parks Corporation (HKSTP), in collaboration with InvestHK, led 16 prominent life and health technology companies to BIO 2025, the world's largest biotechnology event, held in Boston, USA, from June 16 to 19. This year marks the first time HKSTP joined forces with Hong Kong's two leading medical faculties—the LKS Faculty of Medicine at The University of Hong Kong (HKU) and the Faculty of Medicine at The Chinese University of Hong Kong (CUHK) – to form a delegation, showcasing Hong Kong's cutting-edge research capabilities and innovation potential in life sciences and health technologies. The initiative further strengthens Hong Kong's position as a world-class biotech innovation hub. In collaboration with InvestHK, HKSTP joined forces with the LKS Faculty of Medicine at The University of Hong Kong (HKU) and the Faculty of Medicine at The Chinese University of Hong Kong (CUHK) for the first time to form a delegation and led 16 prominent life and health technology companies to showcase at BIO 2025 held in Boston, USA. The HKSTP Pavilion highlighted the groundbreaking technologies and products of its park companies, featuring innovative solutions across diverse fields such as novel drug development, diagnostic technologies, and medical innovation. Among the 16 participating companies, they were the members of HKSTP's incubation programmes including Incu-Bio and ELITE Programme, cutting-edge work from the InnoHK research centers, and other outstanding biotech companies. On the first day of the exhibition, the delegation successfully attracted attention from global industry leaders, corporate partners, and venture capital firms. ADVERTISEMENT During BIO 2025, HKSTP and its park companies made significant strides in fostering cross-border innovation ecosystems and exploring new market opportunities: Immuno Cure , partnering with HKUMed, the developer of the first-in-human novel therapeutic HIV vaccine ICVAX, announced its collaboration with PharmaJet to explore the application of a needle-free vaccination solution, accelerating the global commercialization pathway for ICVAX. , partnering with HKUMed, the developer of the first-in-human novel therapeutic HIV vaccine ICVAX, announced its collaboration with PharmaJet to explore the application of a needle-free vaccination solution, accelerating the global commercialization pathway for ICVAX. HKSTP signed a partnership agreement with DLRC to provide legal advisory services in clinical trials and certification, promoting global ecosystem collaboration and growth. Mr. Albert Wong, CEO of HKSTP, said: 'We are thrilled to partner with two leading medical schools for the first time at BIO 2025, demonstrating Hong Kong's breakthroughs and innovation in life and health technology. This delegation not only deepens collaboration between Hong Kong and top global research institutions but also highlights our unique advantages as a core I&T hub in the Greater Bay Area. With strong policy and funding support from the HKSAR government, Hong Kong will further serve as a bridge connecting Mainland China and global tech partnerships, solidifying its leadership in life sciences innovation.' Ahead of BIO 2025, the delegation participated in the '2025 Biomedical Pitch Competition', co-organized by the Boston Capital Investment Club (BCIC) and HKSTP. The event connects global life and health innovators with investors and business partners. Three HKSTP companies—ARBELE, GenEditBio, and Cogsmart—excelled in the preliminary rounds, competing against over 100 global life sciences firms, with ARBELE, HKUMed's affiliated spin-off company, winning the championship, underscoring Hong Kong's research excellence. Over the past three years, this platform has helped startups secure over USD 100 million in funding and connect with hundreds of international investors and partners, driving further business growth. HKSTP is committed to propelling Hong Kong's life sciences sector onto the global stage, showcasing the city's unique strengths to attract international enterprises and talent. The delegation also organized networking events and visits, enabling Hong Kong companies to engage with overseas investors, leading corporations, and renowned academic institutions, including visits to MIT Professor Robert Langer (Described as 'Edison of Medicine'), Harvard Innovation Labs, Cambridge Innovation Center, and more. This initiative reinforces Hong Kong's sustainable development in life sciences and its role as a global innovation leader. Appendix: List of Park Companies Participating in BIO 2025: ADVERTISEMENT Allegrow Biotech Limited ARBELE Limited Beth Bioinformatics Co., Limited Centre for Translational Stem Cell Biology The Centre for Virology, Vaccinology, and Therapeutics DECODE CURE Limited GenEditBio Limited Great Bay Bio Hong Kong Universal Biologicals Company Limited Immuno Cure Holding (HK) Limited The Institute for Innovation, Translation and Policy Research (ITPR) LEE'S PHARMACEUTICAL (HK) LIMITED Serilink Biotechnology Company Limited Xiaomo Biotech Limited XUXIN (HongKong) Biotechnology Co., Limited Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited Hashtag: #HKSTP The issuer is solely responsible for the content of this announcement. About Hong Kong Science and Technology Parks Corporation Hong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 13 unicorns, more than 15,000 research professionals and over 2,300 technology companies from 25 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc. Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined. Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more. Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues to contribute in stablishing I&T as a pillar of growth for Hong Kong. More information about HKSTP is available at
Zawya
2 days ago
- Zawya
HKSTP Teams Up with HKU and CUHK Medical Schools to Showcase Hong Kong's Life & Health Innovations at BIO International Convention
Seizing Global Business and Investment Opportunities for Sustainable Growth HONG KONG SAR - Media OutReach Newswire - 17 June 2025 - Hong Kong Science and Technology Parks Corporation (HKSTP), in collaboration with InvestHK, led 16 prominent life and health technology companies to BIO 2025, the world's largest biotechnology event, held in Boston, USA, from June 16 to 19. This year marks the first time HKSTP joined forces with Hong Kong's two leading medical faculties—the LKS Faculty of Medicine at The University of Hong Kong (HKU) and the Faculty of Medicine at The Chinese University of Hong Kong (CUHK) - to form a delegation, showcasing Hong Kong's cutting-edge research capabilities and innovation potential in life sciences and health technologies. The initiative further strengthens Hong Kong's position as a world-class biotech innovation hub. The HKSTP Pavilion highlighted the groundbreaking technologies and products of its park companies, featuring innovative solutions across diverse fields such as novel drug development, diagnostic technologies, and medical innovation. Among the 16 participating companies, they were the members of HKSTP's incubation programmes including Incu-Bio and ELITE Programme, cutting-edge work from the InnoHK research centers, and other outstanding biotech companies. On the first day of the exhibition, the delegation successfully attracted attention from global industry leaders, corporate partners, and venture capital firms. During BIO 2025, HKSTP and its park companies made significant strides in fostering cross-border innovation ecosystems and exploring new market opportunities: Immuno Cure, partnering with HKUMed, the developer of the first-in-human novel therapeutic HIV vaccine ICVAX, announced its collaboration with PharmaJet to explore the application of a needle-free vaccination solution, accelerating the global commercialization pathway for ICVAX. HKSTP signed a partnership agreement with DLRC to provide legal advisory services in clinical trials and certification, promoting global ecosystem collaboration and growth. Mr. Albert Wong, CEO of HKSTP, said: "We are thrilled to partner with two leading medical schools for the first time at BIO 2025, demonstrating Hong Kong's breakthroughs and innovation in life and health technology. This delegation not only deepens collaboration between Hong Kong and top global research institutions but also highlights our unique advantages as a core I&T hub in the Greater Bay Area. With strong policy and funding support from the HKSAR government, Hong Kong will further serve as a bridge connecting Mainland China and global tech partnerships, solidifying its leadership in life sciences innovation." Ahead of BIO 2025, the delegation participated in the "2025 Biomedical Pitch Competition", co-organized by the Boston Capital Investment Club (BCIC) and HKSTP. The event connects global life and health innovators with investors and business partners. Three HKSTP companies—ARBELE, GenEditBio, and Cogsmart—excelled in the preliminary rounds, competing against over 100 global life sciences firms, with ARBELE, HKUMed's affiliated spin-off company, winning the championship, underscoring Hong Kong's research excellence. Over the past three years, this platform has helped startups secure over USD 100 million in funding and connect with hundreds of international investors and partners, driving further business growth. HKSTP is committed to propelling Hong Kong's life sciences sector onto the global stage, showcasing the city's unique strengths to attract international enterprises and talent. The delegation also organized networking events and visits, enabling Hong Kong companies to engage with overseas investors, leading corporations, and renowned academic institutions, including visits to MIT Professor Robert Langer (Described as "Edison of Medicine"), Harvard Innovation Labs, Cambridge Innovation Center, and more. This initiative reinforces Hong Kong's sustainable development in life sciences and its role as a global innovation leader. Appendix: List of Park Companies Participating in BIO 2025: Allegrow Biotech Limited ARBELE Limited Beth Bioinformatics Co., Limited Centre for Translational Stem Cell Biology The Centre for Virology, Vaccinology, and Therapeutics DECODE CURE Limited GenEditBio Limited Great Bay Bio Hong Kong Universal Biologicals Company Limited Immuno Cure Holding (HK) Limited The Institute for Innovation, Translation and Policy Research (ITPR) LEE'S PHARMACEUTICAL (HK) LIMITED Serilink Biotechnology Company Limited Xiaomo Biotech Limited XUXIN (HongKong) Biotechnology Co., Limited Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited Hashtag: #HKSTP The issuer is solely responsible for the content of this announcement. About Hong Kong Science and Technology Parks Corporation Hong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 13 unicorns, more than 15,000 research professionals and over 2,300 technology companies from 25 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc. Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined. Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more. Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues to contribute in stablishing I&T as a pillar of growth for Hong Kong. More information about HKSTP is available at Hong Kong Science and Technology Parks Corporation
